Product Description: Epetraborole (GSK2251052) hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole hydrochloride can be used in multidrug-resistant gram-negative pathogens infection research[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C11H17BClNO4
References: [1]Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4./[2]O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98./[3]Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52.
CAS Number: 1234563-16-6
Molecular Weight: 273.52
Compound Purity: 99.63
Research Area: Infection
Solubility: DMSO : 200 mg/mL (ultrasonic)/H2O : ≥ 28 mg/mL
Target: Aminoacyl-tRNA Synthetase;Bacterial
English
Deutsch
